Two phase I trials that pulsed DCs with Wilms’ tumor 1 (WT1) and six GBM TAAs respectively have found these vaccines to be safe in rGBM and ndGBM patients (Phuphanich et al., 2013; Sakai et al., 2015). Here, WT1 is linked to glioblastoma.